okada

1. Erlotinib
2

2. •
1
• γ
•
Erlotinib 3

3. p-
EGFR
stage
1 34 F LUL+ND2a IV Ad Exon21:L858R
2 65 M RUL+ND2a IIIA Ad -
2 7
3 72 F RUL+ND2a IB Ad Exon19:del
2 2

4. 1
2008 8 → Adenocarcinoma

5. 1 34F cT1N0M1
2008 9
adenocarcinoma with mixed subtypes, acinar adenocarcinoma,
bronchioloalveolar carcinoma, non-mucinous, and papillary adnocarcinoma,
pT1aN0M1 stage IV
3

6. 1 34F
2009 6 →

7. 1 34F 1
Erlotinib
2009 7 1 Erlotinib
MRI 7mm

8. 1 34F Erlotinib 3
2009 10 →Erlotinib
11 →CR

9. 2 65
2004 5 Pancoast + +
P/D Adenocarcinoma 45×45×38mm pT3N1M0 stage A
60Gy 2

10. 2 65M 2 7
2006 12 2 7 γ
2 Grade3
CDDP TS-1 2

11. 2 γ 2 3
2009 3 γ 2 3 6
EGFR
1 DOC CDDP 3
4 MRI
1 Grade3

12. 2 6
2010 1 6 EGFR
- Erlotinib

13. 2 Erlotinibi 5
2010 6 Erlotinib 5 →SD

14. 3 72
2006 6 + ND2a
Adenocarcinoma with mixed subtypes,acinar and papillary adenocarcinoma, and
BAC non-mucinous pT2N0M0 stageIB
2006 8 UFT

15. 3 72F 2 2
2008 8 2 2 γ
2008 10 2 Erlotinib

16. 3 72F
2008 10

17. 3 72F
2009 7 EGFR Exon19:del Erlotinib
9 →CR 10

18. • 1 3 CR
• Erlotinib 1 Grade1
2 Grade2
3 Grade1
• EGFR - 2
5 SD

19. Erlotinib
Erlotinib Erlotinib
3 CR
SLX
1 1
11
Erlotinib 170→33 Grade1
γ-knife,
Op GEM CEA
2 +VNR, 3 1
5 SD
8.7→2.2 Grade2
DOC+CDDP,
Erlotinib
9 CR CEA
, Grade1
3 3
10
Erlotinib
Grade1

20. •
•
1) Jackman DM et al . JCO 2006;24:4517-4520
2) Ranson M,et al. J Clin Oncol 2001;19:3267-79
3) Katayama et al. JTO 4 (11) 2009;1415-19

21. • Erlotinib

22. EGFR M
Op(lung), 8
1 73 F LLL+ND3α Ad IIA 6 7
n/a
γ-knife
M γ-knife 1 2
2 77 LUL+ND2a Sq IV
n/a
gefitinib
Ad-sq
3 63 F LUL+ND2a IIB 3
γ-knife negative 2
2
4 68 F RUL+ND2a 8
γ-knife n/a
IIA
M Ad 8
5 79 LUL+ND2a 10
UFT
n/a
IIA
3 CR
Ad Op Exon21:L8
6 34 F LUL+ND2a
11
IV Erlotinib 58R
γ-knife,
M Ad Op GEM
7 65 RUL+ND2a 2 7
negative 5 SD
IIIA +VNR, TS-1
Erlotinib
Ad 9 CR
8 72 F RUL+ND2a 2 2
positive 10
IB Erlotinib